Mei Ri Jing Ji Xin Wen·2025-05-22 23:32Group 1 - Baiyoutai adjusts the development strategy for BAT3306, terminating the ongoing BAT3306-002 study due to reduced necessity for efficacy comparison studies in the approval of biosimilars by regulatory authorities [1] - The decision reflects the intense competition in the PD-1 sector and the challenges in developing biosimilars [1] Group 2 - Tonghua Dongbao plans to transfer 23.1876 million shares of Tebao Bio, accounting for 5.7% of its total share capital, at a price of 56.12 yuan per share, totaling 1.301 billion yuan [2] - This transfer is part of Tonghua Dongbao's long-term strategy for innovation and transformation [2][3] Group 3 - Lijun Group intends to acquire 64.81% of the shares of Imexpharm Corporation (IMP) in Vietnam for approximately 1.587 billion yuan [4] - The acquisition aims to enhance Lijun Group's presence in the overseas market and support its long-term strategy for internationalization and sustainable development [4] Group 4 - The KRAS G12C inhibitor, developed by Jakkos and Elysium, has been approved for use in China for adult patients with locally advanced or metastatic non-small cell lung cancer who have received at least one line of systemic therapy [5] - The domestic market for KRAS G12C inhibitors is highly competitive, with 31 candidates in clinical development and several others nearing approval [5]